---
title: Risk factors for immune-related adverse effects during CPI therapy in patients
  with head and neck malignancies - a single center study
date: '2024-02-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38420014/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240229170544&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'INTRODUCTION: Checkpoint inhibitors, such as PD1 inhibitors, represent
  an important pillar in the therapy of advanced malignancies of the head and neck
  region. The most relevant complications are immune-related adverse effects (irAEs),
  which represent an immense burden for patients. Currently, no sufficient stratification
  measures are available to identify patients at increased risk of irAEs. The aim
  of this retrospective study was to examine whether demographic, histopathological,
  clinical, ...'
disable_comments: true
---
INTRODUCTION: Checkpoint inhibitors, such as PD1 inhibitors, represent an important pillar in the therapy of advanced malignancies of the head and neck region. The most relevant complications are immune-related adverse effects (irAEs), which represent an immense burden for patients. Currently, no sufficient stratification measures are available to identify patients at increased risk of irAEs. The aim of this retrospective study was to examine whether demographic, histopathological, clinical, ...